Presentation to highlight advancements in Hoth's clinical pipeline, including HT-001 for cancer-therapy-induced rash and HT-KIT, a novel oncology program targeting KIT-driven tumors , /PRNewswire/ --Â Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing first-in-class therapeutics for dermatological, oncology, and Alzheimer's, today announced that Chief Executive Officer Robb Knie will be presenting at the upcoming BIO-Europe 2025 Conference, taking place ...